Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 10/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323014 | 0.87 | ALDH1A1 (0.46) | OPRM1POLBALDH1A1KDM4ENPSR1 | |
| SCHEMBL128141 | 0.86 | RPS6KB1 (0.39) | RPS6KB1MALT1MAPT | |
| SCHEMBL123222 | 0.83 | MCOLN2 (0.40) | RPS6KB1OPRM1OPRD1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL123986 | 0.82 | RPS6KB1 (0.41) | RPS6KB1OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL3325655 | 0.76 | RPS6KB1 (0.43) | RPS6KB1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3321649 | 0.76 | OGA (0.39) | — | |
| SCHEMBL3323482 | 0.74 | ACHE (0.39) | RPS6KB1OPRK1POLBMAPT | |
| SCHEMBL3324121 | 0.73 | RPS6KB1 (0.42) | RPS6KB1KIT | |
| SCHEMBL126154 | 0.73 | SLC6A4 (0.41) | RPS6KB1OPRM1OPRD1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL3322453 | 0.71 | RPS6KB1 (0.45) | RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2201002-B1 | 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | RPS6KB1 1468/4885OPRM1 30/4885OPRD1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.